Table 5 Multivariate models on time-to-progression and non-relapse mortality from randomization.

From: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

Factor

TTP

NRM

 

HR (95% CI)

p

HR (95% CI)

p

Age group S2 (vs. S1)

1.19 (0.86–1.63)

0.29

2.20 (0.95–5.08)

0.06

Age group S3 (vs. S1)

0.94 (0.70–1.25)

0.65

1.67 (0.74–3.76)

0.21

Induction therapy (VCD)

0.87 (0.68–1.10)

0.25

–

–

Maintenance strategy (LEN-CR)

1.15 (0.90–1.45)

0.26

–

–

Sex (male)

1.32 (1.03–1.69)

0.03

–

–

ISS stage II

1.50 (1.12–2.00)

0.006

–

–

ISS stage III

1.71 (1.25–2.34)

<0.001

–

–

LDH (>ULN)

1.51 (1.08–2.11)

0.02

–

–

Adverse cytogenetics (yes)

1.91 (1.48–2.46)

<0.001

–

–

IgA subtype (yes)

1.06 (0.80–1.41)

0.69

–

–

WHO PS (>1)

1.17 (0.78–1.74)

0.45

3.49 (1.56–7.80)

0.002

Cardiac/vascular disorders (>1)

–

–

0.75 (0.28–1.97)

0.56

  1. Age groups are defined as: ≤60 years (S1), 61–65 years (S2) and 66–70 years (S3). Adverse cytogenetics were defined as at least one of the following aberrations: deletion17p13, translocation t(4;14), translocation t(14;16), gain 1q21 (>3 copies).
  2. Bold p values are statistically significant.
  3. VCD bortezomib, cyclophosphamide, dexamethasone, LEN lenalidomide, CR complete response, WHO World Health Organization, PS performance status, ISS International Staging System, LDH lactate dehydrogenase, ULN upper limit of normal, Ig immunoglobulin.
Back to article page